Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Pazopanib: carving a niche in a crowded therapeutic landscape

Nature Reviews Clinical Oncology volume 7, pages 362–363 (2010)Cite this article

Subjects

Encouraging data have been reported from a randomized, double-blind, phase III trial comparing pazopanib therapy to placebo in treatment-naive and cytokine-refractory patients with advanced renal-cell carcinoma. The challenge that lies ahead is determining where pazopanib fits into the crowded therapeutic algorithms for this disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. US Food and Drug Administration. FDA approval letter for sorafenib [online], (2010).

  2. US Food and Drug Administration. FDA approval letter for sunitinib [online], (2010).

  3. National Comprehensive Cancer Network Clinical Practice Guidelines. Renal cell carcinoma [online], (2010).

  4. Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061–1068 (2010).

    Article  CAS  Google Scholar 

  5. Sternberg, C. N. et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) [abstract]. J. Clin. Oncol. 27 (Suppl.), 5021 (2009).

    Google Scholar 

  6. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).

    Article  CAS  Google Scholar 

  7. Escudier, B. J. et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC) [abstract]. J. Clin. Oncol. 27 (Suppl.), 5020 (2009).

    Google Scholar 

  8. NCT00720941: Study VEG108844, a study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma [online], (2010).

  9. NCT01064310: A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma [online], (2010).

  10. Heymach, J. et al. Lower baseline levels of plasma hepatocyte growth factor (HGF), IL-6 and IL-8 are correlated with tumor shrinkage in renal cell carcinoma patients treated with pazopanib [abstract]. Mol Cancer. Ther. 8 (12 Suppl.), a11 (2009).

    Article  Google Scholar 

Download references

Acknowledgements

Dr. Pal's research is supported by the NIH Loan Repayment Plan (LRP), the CBCRP 15IB-0140 (California Breast Cancer Research Program Junior IDEA Award) and NIH K12 2K12CA001727-16A1.

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, 91010, CA, USA

    Sumanta Kumar Pal & Robert A. Figlin

Authors
  1. Sumanta Kumar Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Figlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert A. Figlin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pal, S., Figlin, R. Pazopanib: carving a niche in a crowded therapeutic landscape. Nat Rev Clin Oncol 7, 362–363 (2010). https://doi.org/10.1038/nrclinonc.2010.83

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.83

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing